Compare iShares MSCI ACWI ETF (ACWI) vs Stryker Corporation (SYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares MSCI ACWI ETF vs Stryker Corporation — how do they compare? iShares MSCI ACWI ETF trades at $155.73, while Stryker Corporation trades at $328.07 (market cap $126.41B). The key difference: Stryker Corporation pays a 1.07% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, Stryker Corporation nearer its low. Which is the better fit depends on your goals.
| ACWI | SYK | |
|---|---|---|
52-Week High | $159.97 | $403.53 |
52-Week Low | $128.32 | $282.58 |
Market Cap | — | $126.41B |
Sector | — | Technology |
Enterprise Value | — | $138.17B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $157.97, up 1.17% with a bullish technical signal from moving averages. The ETF shows strong institutional interest and positive news flow, with a dividend scheduled for June 2026. Key support lies at $156, while resistance is at $159.
Outlook remains positive due to robust EPS growth and investor inflows into global equity ETFs. Risks include overbought technical conditions and market volatility. The stock's valuation and momentum support a constructive view for long-term investors.
Stryker (SYK) trades at $324.73, down 0.55% on the day, with a bullish technical outlook supported by moving averages. The company maintains strong fundamentals with 2025 revenue of $25.12B, net income of $3.25B, and consistent earnings beats in recent quarters despite a Q1 2026 miss. Analyst consensus remains strongly positive with 72% buy ratings and a $385.30 price target, representing 19% upside potential. Recent developments include new product launches and a strategic acquisition of Amplitude Vascular Systems.
SYK presents a compelling investment case with robust profitability (63.83% gross margin, 15.2% ROE) and strong institutional support. Key risks include cybersecurity incidents impacting operations and premium valuation metrics (P/E 37.58). The stock's current position near pivot point support at $323 suggests potential for recovery toward resistance at $329, supported by positive technical indicators and strong analyst conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
